Choueiri, T. K., Quinn, D. I., Zhang, T., Gurney, H., Doshi, G. K., Cobb, P. W., … Powles, T. (2018). KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. In Journal of Clinical Oncology (Vol. 36, pp. TPS4599–TPS4599). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps4599

Choueiri, Toni K., David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, et al. “KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.” In Journal of Clinical Oncology, 36:TPS4599–TPS4599. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4599.

Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, et al. KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS4599–TPS4599.

Choueiri, Toni K., et al. “KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS4599–TPS4599. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps4599.

Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L, Park SH, Semenov A, Chang WY-H, Wan SM, Poehlein CH, Powles T. KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS4599–TPS4599.